scispace - formally typeset
E

Elham Rahme

Researcher at McGill University

Publications -  268
Citations -  10329

Elham Rahme is an academic researcher from McGill University. The author has contributed to research in topics: Population & Retrospective cohort study. The author has an hindex of 48, co-authored 236 publications receiving 9101 citations. Previous affiliations of Elham Rahme include McGill University Health Centre & Montreal General Hospital.

Papers
More filters
Journal ArticleDOI

Congenital Heart Disease in the General Population Changing Prevalence and Age Distribution

TL;DR: The prevalence of severe CHD increased from 1985 to 2000, but the increase in adults was significantly higher than that observed in children, and in 2000, there were nearly equal numbers of adults and children with severeCHD.
Journal ArticleDOI

The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting.

TL;DR: Analysis of patients endoscoped for nonvariceal upper gastrointestinal bleeding at 18 community and tertiary care institutions between 1999 and 2002 appears to confirm the protective role of endoscopic therapy in patients with high-risk stigmata, and suggest that acute use of PPIs may be associated with a reduction of rebleeding in all patients, and lower mortality in patientsWith high- Risk Stigmata.
Journal ArticleDOI

Magnetic Resonance Cholangiopancreatography: A Meta-Analysis of Test Performance in Suspected Biliary Disease

TL;DR: In this paper, the authors evaluated the overall sensitivity and specificity of Magnetic Resonance Cholangiopancreatography (MRCP) in suspected biliary obstruction and to evaluate clinically important subgroups.
Journal ArticleDOI

Survival Bias Associated with Time-to-Treatment Initiation in Drug Effectiveness Evaluation: A Comparison of Methods

TL;DR: Five methods of studying survival bias associated with time-to-treatment initiation in a drug effectiveness study using medical administrative databases from Quebec, Canada were compared, suggesting a 20% risk reduction of recurrent myocardial infarction or death events.